Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient | Zendy

Marcus Gorschlüter | Zendy; Axel Glasmacher | Zendy; F. Risse | Zendy; B. Klein | Zendy; H. U. Klehr | Zendy; J. Mezger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient

Author(s) -

Marcus Gorschlüter,

Axel Glasmacher,

F. Risse,

B. Klein,

H. U. Klehr,

J. Mezger

Publication year - 1997

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/12.3.593

Subject(s) - medicine , cytarabine , mitoxantrone , chemotherapy , transplantation , induction chemotherapy , daunorubicin , myeloid leukemia , myeloid leukaemia , surgery , oncology , gastroenterology

Immunosuppressed organ transplant recipients have a markedly increased risk of neoplasia. Among these malignancies acute myeloid leukaemia (AML) is rare. However, until now no case of successful chemotherapy has been reported. We present a 39-year-old male patient who developed AML (FAB M4 Eo) 4 years after renal transplantation and achieved a stable complete remission after induction therapy with standard dose cytarabine and daunorubicin. Remission duration is now 11 months. At present the transplant is functioning well after two additional courses of consolidation chemotherapy with high-dose cytarabine combined with mitoxantrone and idarubicine respectively. Cyclosporin A was given during all cycles of chemotherapy. We conclude that intensive chemotherapy in patients with AML following renal transplantation in good performance status is feasible.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research